CD4+ cells treated with DNA methylation inhibitors induce autologous B cell differentiation

Bruce C. Richardson, Michael Liebling, Jerry L. Hudson

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The DNA methylation inhibitor 5-azacytidine induces autoreactivity in cloned CD4+ T cells, but the functional consequences of this response are unknown. We now report that CD4+ T cells treated with 5-azacytidine respond to autologous antigen-presenting cells and induce autologous B cell differentiation without exogenous antigen or mitogen. This mechanism could play a role in some autoimmune diseases characterized by T cell DNA hypomethylation and polyclonal B cell activation.

Original languageEnglish (US)
Pages (from-to)368-381
Number of pages14
JournalClinical Immunology and Immunopathology
Volume55
Issue number3
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

DNA Methylation
Azacitidine
Cell Differentiation
B-Lymphocytes
T-Lymphocytes
Autoantigens
Antigen-Presenting Cells
Mitogens
Autoimmune Diseases
Antigens

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

CD4+ cells treated with DNA methylation inhibitors induce autologous B cell differentiation. / Richardson, Bruce C.; Liebling, Michael; Hudson, Jerry L.

In: Clinical Immunology and Immunopathology, Vol. 55, No. 3, 1990, p. 368-381.

Research output: Contribution to journalArticle

Richardson, Bruce C. ; Liebling, Michael ; Hudson, Jerry L. / CD4+ cells treated with DNA methylation inhibitors induce autologous B cell differentiation. In: Clinical Immunology and Immunopathology. 1990 ; Vol. 55, No. 3. pp. 368-381.
@article{457251bdc6a24029bade702f7c0feedd,
title = "CD4+ cells treated with DNA methylation inhibitors induce autologous B cell differentiation",
abstract = "The DNA methylation inhibitor 5-azacytidine induces autoreactivity in cloned CD4+ T cells, but the functional consequences of this response are unknown. We now report that CD4+ T cells treated with 5-azacytidine respond to autologous antigen-presenting cells and induce autologous B cell differentiation without exogenous antigen or mitogen. This mechanism could play a role in some autoimmune diseases characterized by T cell DNA hypomethylation and polyclonal B cell activation.",
author = "Richardson, {Bruce C.} and Michael Liebling and Hudson, {Jerry L.}",
year = "1990",
doi = "10.1016/0090-1229(90)90125-A",
language = "English (US)",
volume = "55",
pages = "368--381",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - CD4+ cells treated with DNA methylation inhibitors induce autologous B cell differentiation

AU - Richardson, Bruce C.

AU - Liebling, Michael

AU - Hudson, Jerry L.

PY - 1990

Y1 - 1990

N2 - The DNA methylation inhibitor 5-azacytidine induces autoreactivity in cloned CD4+ T cells, but the functional consequences of this response are unknown. We now report that CD4+ T cells treated with 5-azacytidine respond to autologous antigen-presenting cells and induce autologous B cell differentiation without exogenous antigen or mitogen. This mechanism could play a role in some autoimmune diseases characterized by T cell DNA hypomethylation and polyclonal B cell activation.

AB - The DNA methylation inhibitor 5-azacytidine induces autoreactivity in cloned CD4+ T cells, but the functional consequences of this response are unknown. We now report that CD4+ T cells treated with 5-azacytidine respond to autologous antigen-presenting cells and induce autologous B cell differentiation without exogenous antigen or mitogen. This mechanism could play a role in some autoimmune diseases characterized by T cell DNA hypomethylation and polyclonal B cell activation.

UR - http://www.scopus.com/inward/record.url?scp=0025281055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025281055&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(90)90125-A

DO - 10.1016/0090-1229(90)90125-A

M3 - Article

C2 - 1692774

AN - SCOPUS:0025281055

VL - 55

SP - 368

EP - 381

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -